Constitutive Notch pathway activation in murine ZMYM2-FGFR1-induced T-cell lymphomas associated with atypical myeloproliferative disease

Blood

Volumn 117, Issue 25, 2011, Pages 6837-6847

  Ren, MingQiang ^a   Cowell, John K ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR 1; HYBRID PROTEIN; NOTCH RECEPTOR; NOTCH1 RECEPTOR; PHOSPHOTRANSFERASE; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; ZMYM2 FGFR1 FUSION KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; HUMAN; HUMAN CELL; LEUKEMOGENESIS; MOUSE; MYELOPROLIFERATIVE DISORDER; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STEM CELL LEUKEMIA LYMPHOMA SYNDROME; T CELL LYMPHOMA; UPREGULATION;

EID: 79959519809     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-295725     Document Type: Article

References (54)

1. Vega F, Medeiros LJ, Davuluri R, Cromwell CC, Alkan S, Abruzzo LV. t(8;13)-positive bilineal lymphomas: report of 6 cases. Am J Surg Pathol. 2008;32(1):14-20.
2. Abruzzo LV, Jaffe ES, Cotelingam JD, Whang-Peng J, Del Duca V Jr, Medeiros LJ. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol. 1992;16(3):236-245.
3. Suzan F, Guasch G, Terre C, et al. Long-term complete haematological and molecular remission after allogeneic bone marrow transplantation in a patient with a stem cell myeloproliferative disorder associated with t(8;13)(p12;q12). Br J Haematol. 2003;121(2):312-314. (Pubitemid 36560599)
4. Kuskonmaz B, Kafali C, Akcoren Z, Karabulut HG, Akalin I, Tuncer MA. The 8p11 myeloproliferative syndrome in a 3-year-old child. Leuk Res. 2008;32(1):198-199. (Pubitemid 350100842)
5. Wong WS, Cheng KC, Lau KM, et al. Clonal evolution of 8p11 stem cell syndrome in a 14-year-old Chinese boy: a review of literature of t(8;13) associated myeloproliferative diseases. Leuk Res. 2007;31(2):235-238. (Pubitemid 44854189)
6. Tefferi A, Gilliland DG. Oncogenes in myeloproliferative disorders. Cell Cycle. 2007;6(5):550-566. (Pubitemid 46440428)
7. Still IH, Cowell JK. The t(8;13) atypical myeloproliferative disorder: further analysis of the ZNF198 gene and lack of evidence for multiple genes disrupted on chromosome 13. Blood. 1998;92(4):1456-1458. (Pubitemid 28369063)
8. Guasch G, Mack GJ, Popovici C, et al. FGFR1 is fused to the centrosome-associated protein CEP110 in the 8p12 stem cell myeloproliferative disorder with t(8;9)(p12;q33). Blood. 2000;95(5):1788-1796. (Pubitemid 30120844)
9. Popovici C, Zhang B, Gregoire MJ, et al. The t(6; 8)(q27;p11) translocation in a stem cell myeloproliferative disorder fuses a novel gene, FOP, to fibroblast growth factor receptor 1. Blood. 1999;93(4):1381-1389. (Pubitemid 29076154)
10. Jackson CC, Medeiros LJ, Miranda RN. 8p11 myeloproliferative syndrome: a review. Hum Pathol. 2010;41(4):461-476.
11. Baumann H, Kunapuli P, Tracy E, Cowell JK. The oncogenic fusion protein-tyrosine kinase ZNF198/fibroblast growth factor receptor-1 has signaling function comparable with interleukin-6 cytokine receptors. J Biol Chem. 2003;278(18):16198-16208. (Pubitemid 36799743)
12. Dong S, Kang S, Gu TL, et al. 14-3-3 Integrates prosurvival signals mediated by the AKT and MAPK pathways in ZNF198-FGFR1-transformed hematopoietic cells. Blood. 2007;110(1):360-369. (Pubitemid 47026855)
13. Roumiantsev S, Krause DS, Neumann CA, et al. Distinct stem cell myeloproliferative/T lymphoma syndromes induced by ZNF198-FGFR1 and BCR-FGFR1 fusion genes from 8p11 translocations. Cancer Cell. 2004;5(3):287-298. (Pubitemid 38402120)
14. Chen J, Deangelo DJ, Kutok JL, et al. PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder. Proc Natl Acad Sci U S A. 2004;101(40):14479-14484. (Pubitemid 39346774)
15. Mombaerts P, Mizoguchi E, Grusby MJ, Glimcher LH, Bhan AK, Tonegawa S. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 1993;75(2):274-282.
16. Philpott KL, Viney JL, Kay G, et al. Lymphoid development in mice congenitally lacking T cell receptor alpha beta-expressing cells. Science. 1992;256(5062):1448-1452.
17. Aster JC, Pear WS, Blacklow SC. Notch signaling in leukemia. Annu Rev Pathol. 2008;3:587-613. (Pubitemid 351488294)
18. Weng AP, Ferrando AA, Lee W, et al. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science. 2004;306(5694):269-271. (Pubitemid 39336870)
19. Schmitt TM, Zuniga-Pflucker JC. Induction of T cell development from hematopoietic progenitor cells by delta-like-1 in vitro. Immunity. 2002;17(6):749-756. (Pubitemid 35477794)
20. Rossi MR, Laduca J, Cowell JK, Srivastava BI, Matsui S. Genomic analysis of CD8+ NK/T cell line, 'SRIK-NKL', with array-based CGH (aCGH), SKY/FISH and molecular mapping. Leuk Res. 2008;32(3):455-463.
21. Chernova O, Cowell JK. Molecular definition of chromosome translocations involving 10q24 and 19q13 in human malignant glioma cells. Cancer Genet Cytogenet. 1998;105(1):60-68. (Pubitemid 28345994)
22. Ren M, Li X, Cowell JK. Genetic fingerprinting of the development and progression of T-cell lymphoma in a murine model of atypical myeloproliferative disorder initiated by the ZNF198-fibroblast growth factor receptor-1 chimeric tyrosine kinase. Blood. 2009;114(8):1576-1584.
23. Real PJ, Tosello V, Palomero T, et al. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med. 2009;15(1):50-58.
24. Still IH, Chernova O, Hurd D, Stone RM, Cowell JK. Molecular characterization of the t(8; 13)(p11;q12) translocation associated with an atypical myeloproliferative disorder: evidence for three discrete loci involved in myeloid leukemias on 8p11. Blood. 1997;90(8):3136-3141. (Pubitemid 27444208)
25. O'Neil J, Calvo J, McKenna K, et al. Activating Notch1 mutations in mouse models of T-ALL. Blood. 2006;107(2):781-785. (Pubitemid 43076406)
26. Gu TL, Goss VL, Reeves C, et al. Phosphotyrosine profiling identifies the KG-1 cell line as a model for the study of FGFR1 fusions in acute myeloid leukemia. Blood. 2006;108(13):4202-4204. (Pubitemid 44913294)
27. Palomero T, Sulis ML, Cortina M, et al. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med. 2007;13(10):1203-1210. (Pubitemid 47530629)
28. Imbimbo BP. Therapeutic potential of gamma-secretase inhibitors and modulators. Curr Top Med Chem. 2008;8(1):54-61. (Pubitemid 351791047)
29. Mizutani K, Yoon K, Dang L, Tokunaga A, Gaiano N. Differential Notch signalling distinguishes neural stem cells from intermediate progenitors. Nature. 2007;449(7160):351-355. (Pubitemid 47443472)
30. Lin YW, Nichols RA, Letterio JJ, Aplan PD. Notch1 mutations are important for leukemic transformation in murine models of precursor-T leukemia/lymphoma. Blood. 2006;107(6):2540-2543. (Pubitemid 43345580)
31. Kunapuli P, Kasyapa CS, Chin SF, Caldas C, Cowell JK. ZNF198, a zinc finger protein rearranged in myeloproliferative disease, localizes to the PML nuclear bodies and interacts with SUMO-1 and PML. Exp Cell Res. 2006;312(19):3739-3751. (Pubitemid 44637177)
32. Ollendorff V, Guasch G, Isnardon D, Galindo R, Birnbaum D, Pebusque MJ. Characterization of FIM-FGFR1, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation. J Biol Chem. 1999;274(38):26922- 26930.
33. Ashworth TD, Pear WS, Chiang MY, et al. Deletion-based mechanisms of Notch1 activation in T-ALL: key roles for RAG recombinase and a conserved internal translational start site in Notch1. Blood. 2010;116(25):5455-5464.
34. Gómez-del Arco P, Kashiwagi M, Jackson AF, et al. Alternative promoter usage at the Notch1 locus supports ligand-independent signaling in T cell development and leukemogenesis. Immunity. 2010;33(5):685-698.
35. Jeannet R, Mastio J, Macias-Garcia A, et al. Oncogenic activation of the Notch1 gene by deletion of its promoter in Ikaros-deficient T-ALL. Blood. 2010;116(25):5443-5454.
36. Goradia A, Bayerl M, Cornfield D. The 8p11 myeloproliferative syndrome: review of literature and an illustrative case report. Int J Clin Exp Pathol. 2008;1(5):448-456.
37. Lamb LS Jr, Neuberg R, Welsh J, Best R, Stetler-Stevenson M, Sorrell A. T-cell lymphoblastic leukemia/lymphoma syndrome with eosinophilia and acute myeloid leukemia. Cytometry B Clin Cytom. 2005;65(1):37-41. (Pubitemid 40617010)
38. Zhang WW, Habeebu S, Sheehan AM, et al. Molecular monitoring of 8p11 myeloproliferative syndrome in an infant. J Pediatr Hematol Oncol. 2009;31(11):879-883.
39. Chmielecki J, Peifer M, Jia P, et al. Targeted next-generation sequencing of DNAregions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer. Nucleic Acids Res. 2010;38(20):6985-6996.
40. Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity. 2010;32(1):14-27.
41. Pui JC, Allman D, Xu L, et al. Notch1 expression in early lymphopoiesis influences B versus T lineage determination. Immunity. 1999;11(3):299-308. (Pubitemid 29463238)
42. Radtke F, Wilson A, Stark G, et al. Deficient T cell fate specification in mice with an induced inactivation of Notch1. Immunity. 1999;10(5):547-558. (Pubitemid 29262657)
43. Pear WS, Aster JC, Scott ML, et al. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles. J Exp Med. 1996;183(5):2283-2291. (Pubitemid 26158919)
44. Li X, Gounari F, Protopopov A, Khazaie K, von Boehmer H. Oncogenesis of T-ALL and non-malignant consequences of overexpressing intracellular NOTCH1. J Exp Med. 2008;205(12):2851-2861.
45. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66(4):649-661. (Pubitemid 121001701)
46. Allman D, Karnell FG, Punt JA, et al. Separation of Notch1 promoted lineage commitment and expansion/transformation in developing T cells. J Exp Med. 2001;194(1):99-106. (Pubitemid 32660441)
47. Chiang MY, Xu L, Shestova O, et al. Leukemia-associated NOTCH1 alleles are weak tumor initiators but accelerate K-ras-initiated leukemia. J Clin Invest. 2008;118(9):3181-3194.
48. Palomero T, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feedforward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006;103(48):18261-18266. (Pubitemid 44871646)
49. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006;20(15):2096-2109. (Pubitemid 44157460)
50. Palomero T, McKenna K, J ON, et al. Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias. Leukemia. 2006;20(11):1963-1966. (Pubitemid 44614885)
51. Mercher T, Cornejo MG, Sears C, et al. Notch signaling specifies megakaryocyte development from hematopoietic stem cells. Cell Stem Cell. 2008;3(3):314-326.
52. Agerstam H, Jaras M, Andersson A, et al. Modeling the human 8p11-myeloproliferative syndrome in immunodeficient mice. Blood. 2010;116(12):2103-2111.
53. Moellering RE, Cornejo M, Davis TN, et al. Direct inhibition of the NOTCH transcription factor complex. Nature. 2009;462(7270):182-188.
54. Wu Y, Cain-Hom C, Choy L, et al. Therapeutic antibody targeting of individual Notch receptors. Nature. 2010;464(7291):1052-1057.